A Phase 2 Study of a Lower Radiation Therapy Dose to Treat Children and Young Adults With Central Nervous System Germinoma

Full Title

A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas (ACNS2321) (CIRB)

Purpose

Researchers are assessing a lower dose of standard radiation therapy after chemotherapy in young people with germinomas. The patients in this study have germinomas of the central nervous system (brain or spinal cord).  It is hoped that this new approach can destroy germinomas with fewer long-term side effects.

People in this study will get chemotherapy using carboplatin and etoposide plus radiation therapy. Some with also have surgery. Your doctor will explain which combination of therapies will be used.

Who Can Join

To join this study, there are a few conditions. You or your child must:

• Have germinoma of the central nervous system that has not been treated with medication or radiation therapy.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 3 to 29 years.

Contact

For more information about this study or to see if you or your child can join, please call 833-MSK-KIDS.